RDY
Dr. Reddy's Laboratories Ltd.

601
Mkt Cap
$10.77B
Volume
2.51M
52W High
$16.17
52W Low
$12.26
PE Ratio
15.84
RDY Fundamentals
Price
$12.94
Prev Close
$12.92
Open
$12.88
50D MA
$13.83
Beta
0.38
Avg. Volume
1.08M
EPS (Annual)
$0.8029
P/B
2.67
Rev/Employee
$138,447.28
Loading...
Loading...
News
all
press releases
Short Interest in Dr. Reddy's Laboratories Ltd (NYSE:RDY) Increases By 21.7%
Dr. Reddy's Laboratories Ltd (NYSE:RDY - Get Free Report) was the target of a large growth in short interest in the month of December. As of December 31st, there was short interest totaling...
MarketBeat·1d ago
News Placeholder
More News
News Placeholder
Dr. Reddy's Laboratories (RDY) Projected to Post Earnings on Thursday
Dr. Reddy's Laboratories (NYSE:RDY) will be releasing its Q3 25/26 earnings before the market opens on Thursday, January 22. (View Earnings Report at...
MarketBeat·6d ago
News Placeholder
Robeco Institutional Asset Management B.V. Has $182.92 Million Stake in Dr. Reddy's Laboratories Ltd $RDY
Robeco Institutional Asset Management B.V. increased its position in shares of Dr. Reddy's Laboratories Ltd (NYSE:RDY - Free Report) by 7.6% in the 3rd quarter, according to the company in its most...
MarketBeat·15d ago
News Placeholder
Zacks Industry Outlook Highlights Sandoz, Teva Pharmaceuticals and Dr. Reddy's
Sandoz, Teva and Dr. Reddy's emerge as standouts as generic drugmakers lean on biosimilars, complex generics and tighter cost controls.
Zacks·1mo ago
News Placeholder
3 Generic Drug Stocks to Watch Amid Changing U.S. Landscape
Generic drugmakers face U.S. pricing pressure, but TEVA, SDZNY and RDY gain momentum through complex generics and biosimilars.
Zacks·1mo ago
News Placeholder
Virtus Advisers LLC Purchases Shares of 118,945 Dr. Reddy's Laboratories Ltd $RDY
Virtus Advisers LLC acquired a new position in shares of Dr. Reddy's Laboratories Ltd (NYSE:RDY - Free Report) during the 2nd quarter, according to the company in its most recent Form 13F filing with...
MarketBeat·2mo ago
News Placeholder
Aurigene Oncology Limited Announces Encouraging Initial Data From 1st Two Cohorts of Phase 1 Study of AUR112, an Oral Small Molecule Inhibitor of MALT1, in Relapsed/Refractory Lymphoid Malignancies
Aurigene Oncology Limited, a clinical-stage biopharmaceutical company developing novel therapies in oncology, today announced initial clinical results from 1st two cohorts of its ongoing Phase 1...
Business Wire·2mo ago
News Placeholder
Grantham Mayo Van Otterloo & Co. LLC Trims Stock Position in Dr. Reddy's Laboratories Ltd $RDY
Grantham Mayo Van Otterloo & Co. LLC lessened its stake in Dr. Reddy's Laboratories Ltd (NYSE:RDY - Free Report) by 59.0% in the 2nd quarter, according to the company in its most recent filing with...
MarketBeat·2mo ago
News Placeholder
West Family Investments Inc. Buys 23,966 Shares of Dr. Reddy's Laboratories Ltd $RDY
West Family Investments Inc. lifted its stake in Dr. Reddy's Laboratories Ltd (NYSE:RDY - Free Report) by 37.1% during the 2nd quarter, according to its most recent disclosure with the Securities...
MarketBeat·2mo ago
News Placeholder
JPMorgan Chase & Co. Grows Stock Holdings in Dr. Reddy's Laboratories Ltd $RDY
JPMorgan Chase & Co. increased its position in Dr. Reddy's Laboratories Ltd (NYSE:RDY - Free Report) by 157.7% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned...
MarketBeat·2mo ago
<
1
2
...
>

Latest RDY News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.